IOL Chemicals and Pharmaceuticals Limited — Board Meeting, 07-08-2025: Outcome of Board Meeting

IOL Chemicals & Pharma's board has announced a meeting, approving its consolidated financial results for the quarter ended June 30, 2025. Revenue hit ₹551.69 Cr, with profit reaching ₹33.93 Cr. The company is strategically expanding, forming a Wholly Owned Subsidiary in the UK to boost presence and efficiency in UK/EU markets. Domestically, IOLCP is investing ₹5.50 Cr (funded internally) into a new 120 MTPA Minoxidil manufacturing unit (Unit 9B), expected by Dec 2025. This move aims to enhance production capabilities and strengthen its product portfolio.